

State of Oklahoma SoonerCare





Lorbrena® (Lorlatinib) Prior Authorization Form

Drug Information	Member Name:	Date of Birth:	Member ID#:	
Billing Provider Information Provider NPI:		Drug Information	1	
Billing Provider Information Provider NPI:	Pharmacy billing (NDC:) Start Date (or date of next dose):		e (or date of next dose):	
Provider NPI:	Dose: Regimen:			
Prescriber Information Prescriber NPI: Prescriber Name: Specialty: Special	Billing Provider Information			
Prescriber NPI: Prescriber Name:	Provider NPI:Provider Name:		<u></u>	
Prescriber NPI:	Provider Phone: Provider Fax:		эх:	
Criteria For Initial Authorization (Initial approval will be for the duration of 6 months): 1. Diagnosis of non-small cell lung cancer (NSCLC)? Yes No A. If answer is 'yes' to question 1, please check all of the following that apply: Metastatic NSCLC Tumor expresses Anaplastic Lymphoma Kinase (ALK) translocation Lorlatinib will be used as a single-agent Lorlatinib will be used as first-line therapy Lorlatinib will be used as second-line therapy following disease progression on alectinib ceritinib Lorlatinib will be used as third-line or greater therapy following disease progression on crizotinib and 1 other ALK inhibitor (i.e., ceritinib or alectinib) If answer is 'no' to question 1, please provide diagnosis: Additional Information: For Continued Authorization: 1. Date of last dose: No No 2. Does member have any evidence of progressive disease while on lorlatinib? Yes No	Prescriber Information			
Criteria For Initial Authorization (Initial approval will be for the duration of 6 months): 1. Diagnosis of non-small cell lung cancer (NSCLC)? Yes No A. If answer is 'yes' to question 1, please check all of the following that apply: Metastatic NSCLC Tumor expresses Anaplastic Lymphoma Kinase (ALK) translocation Lorlatinib will be used as a single-agent Lorlatinib will be used as first-line therapy Lorlatinib will be used as second-line therapy following disease progression on alectinib ceritinib Lorlatinib will be used as third-line or greater therapy following disease progression on crizotinib and 1 other ALK inhibitor (i.e., ceritinib or alectinib) If answer is 'no' to question 1, please provide diagnosis: Additional Information: For Continued Authorization: 1. Date of last dose: 2. Does member have any evidence of progressive disease while on lorlatinib? Yes No	Prescriber NPI:	Prescriber Name:		
For Initial Authorization (Initial approval will be for the duration of 6 months): 1. Diagnosis of non-small cell lung cancer (NSCLC)? Yes No A. If answer is 'yes' to question 1, please check all of the following that apply: Metastatic NSCLC Tumor expresses Anaplastic Lymphoma Kinase (ALK) translocation Lorlatinib will be used as a single-agent Lorlatinib will be used as first-line therapy Lorlatinib will be used as second-line therapy following disease progression on alectinib ceritinib Lorlatinib will be used as third-line or greater therapy following disease progression on crizotinib and 1 other ALK inhibitor (i.e., ceritinib or alectinib) If answer is 'no' to question 1, please provide diagnosis:Additional Information:	Prescriber Phone:	Prescriber Fax:	Specialty:	
1. Diagnosis of non-small cell lung cancer (NSCLC)? Yes No A. If answer is 'yes' to question 1, please check all of the following that apply: Metastatic NSCLC Tumor expresses Anaplastic Lymphoma Kinase (ALK) translocation Lorlatinib will be used as a single-agent Lorlatinib will be used as first-line therapy Lorlatinib will be used as second-line therapy following disease progression on alectinib ceritinib Lorlatinib will be used as third-line or greater therapy following disease progression on crizotinib and 1 other ALK inhibitor (i.e., ceritinib or alectinib) If answer is 'no' to question 1, please provide diagnosis: Additional Information: For Continued Authorization: 1. Date of last dose: 2. Does member have any evidence of progressive disease while on lorlatinib? Yes No 3. Has the member experienced adverse drug reactions related to lorlatinib therapy? Yes No If yes, please specify adverse reactions: Additional Information:	Criteria			
Date of last dose: Does member have any evidence of progressive disease while on lorlatinib? Yes No Has the member experienced adverse drug reactions related to lorlatinib therapy? Yes No If yes, please specify adverse reactions: Additional Information:	☐ Metastatic NSCL☐ Tumor expresse☐ Lorlatinib will be☐ Lorlatinib will be☐ Ceritinib☐ Lorlatinib will be☐ cerizotinib☐ and 1 consistent of the consistent o	C s Anaplastic Lymphoma Kinase used as a single-agent used as first-line therapy used as second-line therapy foll used as third-line or greater ther other ALK inhibitor (i.e., ceritinib , please provide diagnosis:	(ALK) translocation owing disease progression on alectinib or rapy following disease progression on or alectinib)	
Prescriber Signature: Date:	 Date of last dose: Does member have any e Has the member experien If yes, please specify adverse 	vidence of progressive disease vectors related to the control of t		
	Prescriber Signature:		Date:	

I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge.

Please do not send in chart notes. Specific information will be requested if necessary. Failure to complete this form in full will result in processing delays.

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization throughCoverMyMeds® or SureScripts. All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at AetnaBetterHealth.com/Oklahoma.

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.